# Genmab (GMAB) — Earnings

GMAB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gmab/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.49 |
| EPS estimate | $0.45 |
| EPS surprise | +9.57% |
| Revenue surprise | +1.48% |
| Revenue | $1.2B |
| Revenue estimate | $1.1B |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1434265/000143426526000108/gmab-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/02123ead-a5b3-71e2-09f0-13d0434eb9ce.html) |

Genmab reported Q2 2026 results on August 6, 2026. Earnings per share were $0.49, ahead of the $0.45 estimate by 9.57%. Revenue reached $1.2 billion against a $1.1 billion consensus, a 1.48% beat. Compared with Q2 2025, EPS fell about 9% from $0.54, while revenue rose roughly 30% from $925.0 million. It is the highest quarterly revenue in the table.

Revenue has grown steadily. Annual revenue rose from $2.03 billion in 2022 to $3.74 billion in 2025, up about 84%. Earnings have been far more uneven. Annual EPS was $1.15 in 2022, $0.95 in 2023, $1.75 in 2024 and $1.55 in 2025. The first half of 2026 adds up to $0.57, against $0.85 a year earlier, after weak results of $0.05 in Q4 2025 and $0.08 in Q1 2026. Over the last 20 quarters, Genmab beat the EPS estimate 14 times and missed six times, with surprises ranging from a 140.59% beat to an 88.73% miss.

Genmab has reported its third quarter between November 6 and November 10 in each of the past five years. That points to early or mid-November 2026 for the next report, which will show whether the Q2 revenue level carries into the third quarter.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | $0.45 | $0.49 | 9.57% | $1.1B | $1.2B |
| Q1 2026 | May 7, 2026 | $0.16 | $0.08 | -46.69% | $905.8M | $896.0M |
| Q4 2025 | Feb 17, 2026 | $0.44 | $0.05 | -88.73% | $1.0B | $1.1B |
| Q3 2025 | Nov 6, 2025 | $0.49 | $0.65 | 32.89% | $990.4M | $1.0B |
| Q2 2025 | Aug 7, 2025 | $0.40 | $0.54 | 35.74% | $904.3M | $925.0M |
| Q1 2025 | May 8, 2025 | $0.23 | $0.31 | 29.84% | $736.5M | $715.0M |
| Q4 2024 | Feb 12, 2025 | $0.37 | $0.85 | 127.48% | $894.7M | $895.8M |
| Q3 2024 | Nov 6, 2024 | $0.31 | $0.29 | -6.87% | $828.0M | $803.0M |
| Q2 2024 | Aug 8, 2024 | $0.31 | $0.32 | 1.90% | $732.5M | $789.6M |
| Q1 2024 | May 2, 2024 | $0.19 | $0.29 | 56.69% | $572.0M | $598.1M |
| Q4 2023 | Feb 14, 2024 | $0.31 | $0.14 | -55.49% | $671.2M | $675.3M |
| Q3 2023 | Nov 7, 2023 | $0.33 | $0.46 | 40.95% | $642.9M | $681.0M |
| Q2 2023 | Aug 3, 2023 | $0.29 | $0.30 | 5.21% | $601.1M | $621.0M |
| Q1 2023 | May 10, 2023 | $0.09 | $0.05 | -46.32% | $404.3M | $418.3M |
| Q4 2022 | Feb 22, 2023 | $0.34 | $0.12 | -63.06% | $681.4M | $744.1M |
| Q3 2022 | Nov 9, 2022 | $0.22 | $0.53 | 140.59% | $473.5M | $551.0M |
| Q2 2022 | Aug 10, 2022 | $0.19 | $0.40 | 105.25% | $412.0M | $439.7M |
| Q1 2022 | May 11, 2022 | $0.08 | $0.10 | 24.62% | $300.5M | $296.5M |
| Q4 2021 | Feb 16, 2022 | $0.15 | $0.17 | 10.71% | $389.0M | $400.3M |
| Q3 2021 | Nov 10, 2021 | $0.13 | $0.21 | 58.63% | $339.5M | $357.8M |

## Frequently Asked Questions

### When did Genmab (GMAB) last report earnings?

Genmab last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did GMAB beat earnings estimates?

Yes. Genmab reported EPS of $0.49 for Q2 2026 against a $0.45 estimate — a 9.57% beat.

### How much revenue did GMAB report last quarter?

Genmab reported $1.2B in revenue for Q2 2026, against a consensus estimate of $1.1B.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).